Cargando…
484. Clinical Description of SARS-CoV-2 Infection in Patients with Primary Antibody Deficiency Who Received Tixagevimab/Cilgavimab Prophylaxis
BACKGROUND: Patients with primary antibody deficiency are known to be associated with a higher risk of SARS-CoV-2 infection, complications, and mortality. Tixagevimab/Cilgavimab prophylaxis has shown efficacy in reducing hospitalization and mortality. We aim to describe the clinical characteristics...
Autores principales: | Lim, Sung Min, Shin, Je Hee, Baek, Jee Yeon, Lee, Ji Young, Kang, Ji-Man, Ahn, Jong Gyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677890/ http://dx.doi.org/10.1093/ofid/ofad500.554 |
Ejemplares similares
-
Tixagevimab and cilgavimab for COVID-19 prophylaxis
Publicado: (2022) -
Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab–cilgavimab
por: Solera, Javier T, et al.
Publicado: (2023) -
Safety and efficacy of pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) in patients with glomerular diseases who received rituximab
por: Sciascia, Savino, et al.
Publicado: (2023) -
Tixagevimab + Cilgavimab: First Approval
por: Keam, Susan J.
Publicado: (2022) -
Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi
por: Zamprogna, Giulia, et al.
Publicado: (2023)